Pathology is the foundation of oncology decisions. Learn the few sections that truly drive treatment — diagnosis, grade, margins, nodes, and biomarkers.
MS
Dr. Motaz Shieban
Surgical oncologist and regenerative medicine specialist.
Key Takeaways
Pathology is the foundation of oncology decisions; learn the few sections that truly drive treatment.
Read the report as a structured whole: diagnosis, grade, extent, margins, nodes, and biomarkers.
When the clinical picture and pathology do not match, consider a pathology review.
Pathology reports are written for clinicians. Patients often receive them at a stressful moment and search for one word -- "malignant," "aggressive," "clear margins." That approach increases anxiety and reduces understanding.
A better approach is to read pathology as a structured document.
I have seen patients spiral into panic after reading a pathology report on their own, fixating on a single word while missing the overall picture. I have also seen patients who took the time to understand the structure of the report arrive at their consultation with focused questions that led to more productive conversations. This article is designed to help you be the second type of patient.
Why pathology matters so much in oncology
Pathology is the definitive source of diagnostic information in cancer care. While imaging can show the size and location of a tumor, only pathology can tell us what the tumor actually is at the cellular level. Treatment decisions in oncology -- which surgery to perform, whether chemotherapy is needed, which targeted therapies might work, how aggressive the follow-up schedule should be -- all depend on the pathology report.
A pathology report is not a simple yes-or-no document. It is a detailed assessment that provides multiple data points, each of which contributes to the overall treatment plan. Reading it as a structured document, rather than scanning for a single reassuring or alarming word, gives you a much more accurate understanding of your situation.
1. Diagnosis: what is the tumor, exactly?
This is the most important line. It usually includes histologic type, invasive vs in situ, and primary vs metastatic.
What this means in practice
The diagnosis line tells you the name of the tumor. This is more specific than "cancer." It includes the histologic type (what kind of cells the tumor is made of), whether the tumor is invasive (growing into surrounding tissues) or in situ (confined to its original location), and whether it appears to be a primary tumor (originating in this location) or a metastasis (having spread from somewhere else).
For example, a breast pathology report might say "invasive ductal carcinoma" -- this tells you the tumor arises from the ductal cells of the breast, and it is invasive (not confined to the duct). A different report might say "ductal carcinoma in situ (DCIS)" -- this tells you the abnormal cells are still contained within the duct and have not invaded surrounding tissue. These two diagnoses lead to very different treatment plans.
The precision of the diagnosis matters because different histologic types of cancer in the same organ can behave very differently and respond to different treatments. Two patients with "lung cancer" may have completely different diseases if one has adenocarcinoma and the other has squamous cell carcinoma.
pathologydiagnosispatient-education
Related Articles
2. Grade: how aggressive does it look?
Grade describes how abnormal tumor cells appear and often correlates with behavior.
What this means in practice
Grading systems vary by cancer type, but they generally assess how different the cancer cells look from normal cells. Low-grade tumors (grade 1) tend to look more like normal tissue and often behave less aggressively. High-grade tumors (grade 3) look more abnormal and tend to grow and spread more quickly.
It is important to understand that grade is a description of appearance, not a prediction. A high-grade tumor does not guarantee a poor outcome, and a low-grade tumor does not guarantee a good one. Grade is one factor among many that clinicians use to build the overall risk profile.
Some cancers use specific grading systems. Breast cancer often uses the Nottingham grading system, which scores three features (tubule formation, nuclear grade, and mitotic rate) to produce a combined grade. Prostate cancer uses the Gleason scoring system, which grades the two most common architectural patterns seen in the tissue. Understanding the specific grading system used for your cancer helps you interpret the report correctly.
Common misconceptions about grade
Patients often equate grade with stage, but these are different concepts. Grade describes the cellular appearance of the tumor. Stage describes the extent of disease spread. A low-grade tumor can be at an advanced stage (widely spread despite looking relatively normal under the microscope), and a high-grade tumor can be at an early stage (very abnormal-looking cells that have not yet spread).
3. Size and extent: how far did it go locally?
Look for tumor size, depth of invasion, and extension into adjacent structures.
What this means in practice
The pathology report will describe the physical dimensions of the tumor (usually in centimeters or millimeters) and how deeply it has invaded into the surrounding tissue. In some cancers, depth of invasion is a critical staging criterion. For example, in colon cancer, whether the tumor invades through the muscular wall of the colon directly affects the stage and the recommendation for adjuvant chemotherapy.
Extension into adjacent structures means the tumor has grown beyond its organ of origin into nearby tissues. This finding usually indicates a more advanced local stage and may influence the extent of surgery needed or the addition of radiation therapy.
Understanding size and extent helps you grasp why your surgical team may recommend a particular operation or why additional treatment may be recommended after surgery.
4. Margins: was tumor at the cut edge?
Margins are often described as "negative" or "positive." A positive margin is tumor touching ink.
What this means in practice
When a tumor is surgically removed, the pathologist examines the outer edges of the specimen -- the margins -- to determine whether cancer cells extend to the edge of what was removed. The specimen is typically coated in ink so that the actual cut edge can be identified under the microscope.
A "negative" or "clear" margin means no tumor cells are seen at the inked edge. A "positive" margin means tumor cells are touching the ink, which suggests that cancer may remain in the body. A "close" margin means tumor cells are near the ink but not touching it, and the significance of this varies by cancer type and location.
The distance of the tumor from the margin is often reported in millimeters. Whether a margin is "adequate" depends on the type of cancer, its location, and the treatment plan. There is no universal number that constitutes a safe margin across all cancers. For more detail on this topic, see the companion article on margins in this series.
5. Lymphovascular invasion (LVI) and perineural invasion (PNI)
These features can correlate with higher risk patterns and may influence adjuvant treatment decisions.
What this means in practice
Lymphovascular invasion means that tumor cells are seen within lymphatic or blood vessels in the tissue specimen. This is significant because it suggests the tumor has access to the lymphatic or vascular system, which is one of the mechanisms by which cancer spreads to lymph nodes or distant organs.
Perineural invasion means that tumor cells are growing along or around nerves. This can correlate with a higher risk of local recurrence and may influence decisions about additional treatment after surgery, particularly radiation therapy.
Neither LVI nor PNI alone determines the treatment plan, but they are factors that clinicians weigh when assessing overall risk. Their presence may tip the balance toward recommending adjuvant therapy in situations where the decision is otherwise borderline.
6. Lymph nodes: how many were examined and involved?
Look for number examined, number positive, and extranodal extension.
What this means in practice
If lymph nodes were removed during surgery (either through a sentinel node biopsy or a more extensive lymph node dissection), the pathology report will describe how many nodes were examined and how many contained cancer.
The number of nodes examined matters because it reflects the adequacy of the surgical sampling. In colon cancer, for example, guidelines recommend examining a minimum number of lymph nodes to ensure accurate staging. If too few nodes are examined, the staging may be unreliable.
The number of positive nodes directly affects the stage and often influences recommendations for adjuvant therapy. In many cancers, the presence of lymph node metastases is one of the strongest predictors of recurrence risk.
Extranodal extension means that cancer has grown through the capsule of the lymph node into surrounding fat. This is generally considered a higher-risk finding and may influence treatment decisions in some cancer types.
7. Biomarkers: what does the tumor express?
Biomarkers differ by cancer type. The key is understanding what the marker changes in treatment options.
What this means in practice
Biomarkers are molecular characteristics of the tumor that provide information about its biology and, critically, about which treatments are likely to be effective. The specific biomarkers tested depend on the cancer type.
In breast cancer, the key biomarkers include estrogen receptor (ER), progesterone receptor (PR), and HER2. ER and PR positivity means the tumor grows in response to hormones, and hormonal therapy can be effective. HER2 positivity means the tumor overexpresses a growth factor receptor, and targeted HER2 therapies can be used.
In colorectal cancer, key biomarkers include mismatch repair (MMR) status and specific gene mutations (such as KRAS, NRAS, and BRAF) that determine eligibility for certain targeted therapies and immunotherapy.
In lung cancer, multiple molecular markers (EGFR mutations, ALK rearrangements, PD-L1 expression, and others) guide the selection of targeted therapies and immunotherapy.
The important principle is that biomarkers are not just descriptive -- they are prescriptive. They directly determine which treatments you may or may not benefit from. If your pathology report includes biomarker results that you do not understand, ask your oncologist specifically: "What does this marker mean for my treatment options?"
8. TNM elements: the staging language
Pathology contributes to staging, but imaging and clinical context also matter.
What this means in practice
The TNM system is the standard language for cancer staging. T describes the primary tumor (size and local extent), N describes regional lymph node involvement, and M describes distant metastasis. The pathology report contributes the pathological T and N categories (prefixed with "p" -- for example, pT2 N1), while the M category usually comes from imaging.
The pathological stage may differ from the clinical stage that was estimated before surgery based on imaging. The pathological stage is generally considered more accurate because it is based on direct examination of the tissue rather than imaging interpretation.
Understanding that staging is a composite assessment -- not a single test result -- helps you understand why your stage might change after surgery and why the post-surgical treatment plan might differ from what was discussed preoperatively.
When to consider a second pathology review
When the tumor behaves differently than the report suggests
When treatment options depend heavily on subtype or biomarkers
When the sample is small or borderline
When there are conflicting reports
What this means in practice
Pathology is performed by highly trained specialists, but it is not infallible. Certain diagnoses are difficult, certain tissue samples are suboptimal, and certain distinctions between tumor subtypes require specialized expertise. Second pathology reviews are a standard and accepted part of oncology care, not a sign of distrust.
A second review is particularly valuable when the diagnosis is rare, when the distinction between two subtypes changes the treatment plan significantly, when biomarker results are borderline or discordant, or when the clinical behavior of the tumor does not match what the pathology would predict.
Many cancer centers routinely review outside pathology before initiating treatment. If yours does not, and you have concerns about the accuracy of the report, it is entirely reasonable to request one.
Common misconceptions about pathology reports
"The pathology report is the final answer"
The pathology report is a critical input, but it is not the final answer in isolation. Treatment decisions are made by integrating pathology with imaging, clinical examination, patient preferences, comorbidities, and the collective expertise of a multidisciplinary team.
"I should be able to understand every word"
Pathology reports use technical medical terminology that is designed for communication between pathologists and clinicians. Not understanding every term does not mean you are uninformed -- it means the report was not written for a general audience. Focus on the key sections outlined in this article and ask your clinician to explain the terms that are most relevant to your treatment.
"If the report says clear margins, I am cured"
Clear margins mean that no cancer was seen at the cut edge of the specimen. This is important and positive, but it does not guarantee that no cancer cells remain elsewhere in the body. Margins address local control. Systemic risk (the risk of microscopic disease elsewhere) is assessed through staging, biomarkers, and clinical judgment.
When to seek help
If you receive a pathology report and feel overwhelmed, that is normal. Do not try to interpret every line on your own. Instead, note the sections you do not understand and bring them to your next consultation as specific questions. Your oncologist and surgical team expect this and are equipped to walk you through the report section by section.
If there is a significant delay between receiving the report and your next appointment, call the clinic and ask whether the key findings can be discussed by phone. Waiting days or weeks with an uninterpreted report causes unnecessary anxiety.
Summary
A pathology report is not a verdict. It is a structured input into a larger decision system. Understanding the key sections -- diagnosis, grade, size and extent, margins, lymphovascular and perineural invasion, lymph nodes, biomarkers, and TNM staging -- reduces fear and improves the quality of conversations with your treating team. You do not need to become a pathologist to read your report effectively. You need to know which sections matter most, what they mean for your treatment, and when to ask for clarification.
Educational content only. This article does not replace diagnosis, emergency care, or treatment by your local licensed clinicians.